摘要
目的探讨胰岛素输注治疗初诊糖尿病(DM)的临床疗效及对胰岛β细胞功能的影响。方法将62例初诊DM患者随机分为两组,各31例,分别予以胰岛素泵持续皮下输注(CSⅡ组)与多次皮下注射(MSⅡ组)短期强化治疗。结果治疗后,两组血糖及血脂水平均显著改善(P<0.05),组间无明显差异(P>0.05);CSⅡ组的血糖达标时间较MSⅡ组显著缩短(P<0.05),血糖达标时间及治疗2周时的胰岛素日用量均显著低于MSⅡ组(P<0.05);CSⅡ组的胰岛素抵抗及胰岛β细胞功能均较MSⅡ组显著改善(P<0.05)。结论 CSⅡ用于治疗初诊DM患者具有显著疗效,相比于MSⅡ能减少胰岛素用量,缩短血糖达标时间,改善胰岛素抵抗以及胰岛β细胞功能,值得临床推广。
Objective To investigate the clinical efficacy of insulin infusion in treating newly diagnosed diabetes（ DM） and its influence on pancreatic β cell function. Methods 62 cases of newly diagnosed DM patients were randomly divided into two groups,31 cases in each group. CSⅡ group was treated with subcutaneous insulin injection, and MSⅡ group was treated with multiple subcutaneous with short- term intensive treatment. Results After treatment,the glucose and lipid levels of the two groups were significantly improved（ P〈0. 05）, with no significant difference between the two groups（ P〈0. 05）; the blood glucose time of the CSⅡ group was significantly shorter than MSⅡ group（ P〈0. 05）; the daily dose of insulin when blood glucose and 2 weeks of treatment in the CSⅡ group was significantly lower than the MSⅡ group（ P〈0. 05）; the insulin resistance and pancreatic β- cell function in the CSⅡ group was significantly improved compared with the MSⅡ group（ P〈0. 05）. Conclusion CSⅡ in treating newly diagnosed DM has significant efficacy,compared with MSⅡ, it can reduce the amount of insulin, shorten the time of blood glucose, improve insulin resistance and pancreaticβ- cell function,which is worthy of clinical promotion.
出处
《中国药业》
CAS
2016年第1期41-43,共3页
China Pharmaceuticals
关键词
糖尿病
胰岛素
持续皮下输注
胰岛Β细胞功能
diabetes
insulin
continuous subcutaneous infusion
pancreatic β-cell function
